Pomerantz LLP investigates GSK securities fraud claims.

Pomerantz LLP is investigating GSK plc for potential securities fraud or unlawful business practices. The investigation concerns the company's July 2025 press release announcing a negative FDA vote on its Blenrep drug, which led to a 4.73% drop in ADR price. Investors who held GSK shares during this time are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

GSK plc (GSK) has received a significant boost with the UK approval of Blujepa, a novel oral antibiotic designed to treat uncomplicated urinary tract infections. This approval marks a milestone in the company's innovative portfolio, as it introduces the first new class of oral antibiotics in several decades. The approval comes following substantial Phase 3 trial outcomes, demonstrating the drug's effectiveness against drug-resistant bacteria [1].

Analysts are cautiously optimistic about the implications of this approval. The average one-year price target for GSK plc is $38.39, with predictions ranging from $45.00 to $33.91. This average target suggests a potential downside of 3.81% from the current price of $39.91. While the outlook is mixed, the consensus recommendation from 10 brokerage firms rates GSK as a "Hold," indicating a balanced view on the stock's potential [1].

GuruFocus estimates suggest a GF Value of $44.64 for GSK plc in one year, projecting an upside potential of 11.85% from the current price. This estimate is derived from historical trading multiples, past business growth, and anticipated performance metrics. Despite the positive outlook, investors should remain vigilant, as Pomerantz LLP is currently investigating GSK for potential securities fraud or unlawful business practices concerning its July 2025 press release on the Blenrep drug [1].

In light of these developments, investors are advised to stay informed and consider seeking legal advice if they held GSK shares during the time of the Blenrep announcement. Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, is available to assist investors who may have been affected.

References:
[1] https://www.gurufocus.com/news/3083978/gsk-gsk-receives-uk-approval-for-new-antibiotic-blujepa